Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine

Trial Profile

Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
    • 06 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
    • 28 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top